Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aussie Biotech Biota Closer To Resolution With GSK On Relenza Suit

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Biota Holdings' lawsuit with GlaxoSmithKline over antiviral influenza vaccine Relenza (zanamivir) is getting closer to resolution, the Melbourne, Australia-based biotech told PharmAsia News

You may also be interested in...



GSK’s Pre-Pandemic Flu Vaccine To Get Priority Review In Japan

TOKYO - Reflecting its growing concerns about new types of influenza outbreaks, Japan's Ministry of Health, Labor and Welfare will conduct a priority review of GlaxoSmithKline K.K.'s pre-pandemic vaccine, a GSK spokesman and ministry officials said Sept. 5

GSK’s Pre-Pandemic Flu Vaccine To Get Priority Review In Japan

TOKYO - Reflecting its growing concerns about new types of influenza outbreaks, Japan's Ministry of Health, Labor and Welfare will conduct a priority review of GlaxoSmithKline K.K.'s pre-pandemic vaccine, a GSK spokesman and ministry officials said Sept. 5

Aussie Biotech Biota Completes Phase II Trials for Relenza Follow-On; Phase III To Be Conducted In Japan, Taiwan, Hong Kong and Korea

PERTH, Australia - Australian biotech Biota completed Phase II trials for its second-generation influenza compound CS-8958; the trials successfully met all endpoints, the company announced July 31

UsernamePublicRestriction

Register

LL1132600

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel